SCHEMBL6500650

SCHEMBL6500650

CCOC(=O)CCCOc1ccc(NC(=O)OC(C)(C)C)c([N+](=O)[O-])c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.52
KMT2A Q03164 7/20 0.52
MAPK1 P28482 4/20 0.52
LMNA P02545 3/20 0.52
KDM4E B2RXH2 1/20 0.51
RAB9A P51151 7/20 0.49
NPC1 O15118 6/20 0.49
CYP1A2 P05177 3/20 0.49
CYP2C9 P11712 2/20 0.49
SMN1; SMN2 Q16637 5/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
PKM P14618 1/20 0.48
POLB P06746 1/20 0.48
MEN1 O00255 4/20 0.47
NFKB1 P19838 1/20 0.46
NFKB2 Q00653 1/20 0.46
RELA Q04206 1/20 0.46
CYP2C19 P33261 2/20 0.46
NPSR1 Q6W5P4 2/20 0.46
ALDH1A1 P00352 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8664998 0.89 TDP1 (0.56) MAPTKMT2AMAPK1LMNARAB9A
SCHEMBL6490315 0.86 KMT2A (0.60) MAPTKMT2AMAPK1LMNAKDM4E
SCHEMBL28885280 0.86 MAPT (0.61) MAPTKMT2AMAPK1LMNARAB9A
SCHEMBL6492339 0.83 BRD4 (0.46) MAPTL3MBTL1TDP1
SCHEMBL6490865 0.82 KMT2A (0.57) MAPTKMT2AMAPK1LMNAKDM4E
SCHEMBL13244232 0.82 MAPT (0.53) MAPTKMT2AMAPK1LMNAKDM4E
SCHEMBL7371023 0.80 SMN1; SMN2 (0.48) MAPTKMT2AMAPK1CYP1A2CYP2C9
SCHEMBL28526955 0.79 SMN1; SMN2 (0.51) MAPTKMT2AMAPK1LMNARAB9A
SCHEMBL7066309 0.79 RAB9A (0.47) MAPTKMT2AMAPK1LMNARAB9A
SCHEMBL5562070 0.79 KMT2A (0.50) MAPTKMT2AMAPK1RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014812-A1 Benzimidazole compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-01-20 US disclosed
WO-2004108686-A2 BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014812-A1 Benzimidazole compounds SLC5A1, SLC5A2, G6PD MAPT 3168/4885KMT2A 561/4885MAPK1 1334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.